Recurrence characteristics after focal salvage HDR brachytherapy in prostate cancer

被引:5
|
作者
Rasing, Marnix J. A. [1 ,3 ]
Peters, Max [1 ]
van Son, Marieke [2 ]
Moerland, Marinus A. [1 ]
Eppinga, Wietse [1 ]
van de Pol, Sandrine M. G. [1 ]
Noteboom, Juus [1 ]
Lagendijk, Jan [1 ]
vanZyp, Jochem R. N. van der Voort [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Radiat Oncol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[2] Univ Amsterdam, Med Ctr, Dept Urol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Med Ctr Utrecht, Dept Radiat Oncol, Q01 1 05,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
关键词
Brachytherapy; HDR; Prostate cancer; Recurrence; Focal salvage; DOSE-RATE BRACHYTHERAPY; DEFINITIVE RADIATION-THERAPY; LOCAL RECURRENCE; FAILURE; MRI; RADIOTHERAPY; TOXICITY; EFFICACY; PATTERNS;
D O I
10.1016/j.radonc.2023.109495
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Radiorecurrent prostate cancer is often confined to the prostate, predominantly near the index lesion. The purpose of this study was to look at recurrence characteristics in patients treated with focal salvage high dose-rate (HDR) brachytherapy.Materials and methods: Patients treated with MRI-guided HDR brachytherapy, with a single fraction of 19 Gy from July 2013 to October 2021 as focal salvage treatment, were prospectively included in the current study. Imaging data were collected regarding the occurrence of local, regional and distant recurrences, including location of local recurrences (LR) in relation to the HDR radiotherapy field.Results: One hundred seventy-five patients were included after focal salvage HDR brachytherapy (median follow-up 36 months (IQR 23-50)). Three-years biochemical recurrence-free survival, LR-free survival, in-field LR-free survival, out-of-field LR-free survival, any-recurrence-free survival and ADT-free survival were 43% (95%CI 34%-52%), 51% (41%-61%), 70% (61%-80%), 92% (88%-97%), 42% (32%-52%) and 86% (80%-92%), respectively. Larger GTV-size and shorter PSA doubling time were associated with in-field LR in multivariable analysis.Conclusion: After focal salvage HDR brachytherapy with a dose of 1x19 Gy for local prostate cancer recurrence, subsequent recurrences are mostly local and in-field. (c) 2023 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 180 (2023) 1-7 This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Recurrence characteristics in prostate cancer patients after (salvage) focal HDR brachytherapy
    Rasing, M.
    Peters, M.
    van Son, M.
    Lagendijk, J.
    Moerland, M.
    van de Pol, S.
    Eppinga, W.
    Noteboom, J.
    van Zyp, J. van der Voort
    [J]. RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S537 - S538
  • [2] Focal salvage HDR brachytherapy for prostate cancer recurrence after primary external radiotherapy
    Djupvik, L.
    Tafjord, G.
    Russnes, K. M.
    Gustafsson, H.
    Lilleby, W.
    Hellebust, T. P.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S115 - S115
  • [3] Salvage HDR-Brachytherapy in Treating the Recurrence of Prostate Cancer after Radiotherapy
    Jiang, P.
    Zinsser, F.
    Pahl, R.
    Siebert, F. -A
    van der Horst, C.
    Galalae, R.
    Dunst, J.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2015, 191 : S9 - S10
  • [4] Salvage HDR brachytherapy for prostate cancer recurrence: comparison of two fraction schedules
    Stankiewicz, M.
    Kellas-Sleczka, S.
    Szlag, M.
    Wojcieszek, P.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S518 - S520
  • [5] Salvage partial brachytherapy for prostate cancer recurrence after primary brachytherapy
    Sasaki, Hiroshi
    Kido, Masahito
    Miki, Kenta
    Kuruma, Hidetoshi
    Takahashi, Hiroyuki
    Aoki, Manabu
    Egawa, Shin
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (06) : 572 - 577
  • [6] Salvage partial brachytherapy for prostate cancer recurrence after primary brachytherapy
    Tanaka, M.
    Sasaki, H.
    Miki, K.
    Egawa, S.
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 : 101 - 101
  • [7] MRI-GUIDED FOCAL SALVAGE HDR BRACHYTHERAPY FOR LOCALLY RECURRENT PROSTATE CANCER
    Joseph, Lisa
    Beiki-Ardakani, Akbar
    Weersink, Robert
    Rink, Alexandra
    Lao, Bernadeth
    Warde, Padraig
    Catton, Charles
    Bayley, Andrew
    Menard, Cynthia
    Helou, Joelle
    Berlin, Alejandro
    Sundaramurthy, Aravind
    Chung, Peter
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S6 - S6
  • [8] Salvage brachytherapy for prostate cancer biochemical recurrence after radiotherapy
    Polo Rubio, Alfredo
    Henriquez Lopez, Ivan J.
    [J]. ARCHIVOS ESPANOLES DE UROLOGIA, 2012, 65 (01): : 145 - 157
  • [9] Salvage HDR brachytherapy for localised recurrent prostate cancer after primary irradiation
    Stankiewicz, M.
    Wojcieszek, P.
    Lelek, P.
    Krzysztofiak, T.
    Kellas-Sleczka, S.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S1096 - S1097
  • [10] Salvage Brachytherapy in Prostate Cancer after Radiation Failure: HDR vs LDR
    Henriquez Lopez, I.
    Gonzalez, C.
    Olivera Vegas, J.
    Gutierrez, C.
    Cabeza Rodriguez, M. D. L. A.
    Valero Albarran, J.
    Rodriguez Villalba, S.
    Hervas, A.
    Sancho Pardo, G.
    Alvarez Gonzalez, A.
    Zapatero, A.
    Cuesta-Alvaro, P.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E117 - E118